Cargando…

Should older adult pneumococcal vaccination recommendations change due to decreased vaccination in children during the pandemic? A cost-effectiveness analysis

BACKGROUND: The COVID-19 pandemic is causing declines in childhood immunization rates. We examined potential COVID-19-related changes in pediatric 13-valent pneumococcal conjugate vaccine (PCV13) use, subsequent impact on childhood and adult pneumococcal disease rates, and how those changes might af...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Kenneth J., Wateska, Angela R., Nowalk, Mary Patricia, Lin, Chyongchiou J., Harrison, Lee H., Schaffner, William, Zimmerman, Richard K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215512/ https://www.ncbi.nlm.nih.gov/pubmed/34167834 http://dx.doi.org/10.1016/j.vaccine.2021.06.037

Ejemplares similares

Cost-Effectiveness of Newly Recommended Pneumococcal Vaccination Strategies in Older Underserved Minority Adults in the USA
por: Smith, Kenneth J., et al.
Publicado: (2022)

Cost-effectiveness of increasing vaccination in high-risk adults aged 18–64 Years: a model-based decision analysis
por: Wateska, Angela R., et al.
Publicado: (2018)

Potential Cost-Effectiveness of a Universal Influenza Vaccine in Older Adults
por: France, Glenson, et al.
Publicado: (2018)

Differential Gene Expression Elicited by Children in Response to the 2015–2016 Live Attenuated vs. Inactivated Influenza Vaccine
por: Zimmerman, Richard, et al.
Publicado: (2017)

The impact of physical frailty on the response to inactivated influenza vaccine in older adults
por: Moehling, Krissy K., et al.
Publicado: (2020)

Cost-effectiveness of programs to eliminate disparities in elderly vaccination rates in the United States
por: Michaelidis, Constantinos I, et al.
Publicado: (2014)

Factors associated with in-office influenza vaccination by U.S. pediatric providers
por: Lin, Chyongchiou Jeng, et al.
Publicado: (2013)

1436. Risk Factors for Invasive Pneumococcal Disease in Adults ≥65 Years Old Following Pneumococcal Conjugate Vaccine Recommendation
por: Almendares, Olivia M, et al.
Publicado: (2018)

1055 Antibody Response to Intradermal and High Dose Influenza Vaccine in 2012-13 Among Adults Who Did and Did Not Respond to Standard Dose Vaccine in 2011-12
por: Sundaram, Maria, et al.
Publicado: (2014)

Should Pneumococcal Vaccines Eliminate Nasopharyngeal Colonization?
por: McDaniel, Larry S., et al.
Publicado: (2016)

Maintaining Vaccine Delivery Following the Introduction of the Rotavirus and Pneumococcal Vaccines in Thailand
por: Lee, Bruce Y., et al.
Publicado: (2011)

Decrease in Pneumococcal Co-Colonization following Vaccination with the Seven-Valent Pneumococcal Conjugate Vaccine
por: Valente, Carina, et al.
Publicado: (2012)

Current Recommendations for Pneumococcal Vaccination of Children and Adults
por: Fakhraei, Hossein, et al.
Publicado: (2015)

Standing orders for influenza and pneumococcal polysaccharide vaccination: Correlates identified in a national survey of U.S. Primary care physicians
por: Albert, Steven M, et al.
Publicado: (2012)

The hidden societal cost of antibiotic resistance per antibiotic prescribed in the United States: an exploratory analysis
por: Michaelidis, Constantinos I., et al.
Publicado: (2016)

Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia
por: Ordóñez, Jaime E, et al.
Publicado: (2014)

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
por: Ngamprasertchai, Thundon, et al.
Publicado: (2023)

Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population
por: Polistena, Barbara, et al.
Publicado: (2022)

180. Impact of Pneumococcal Conjugative Vaccine on Antibiotic Resistant Invasive Pneumococcal Disease in the United States
por: Bajema, Kristina, et al.
Publicado: (2020)

Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands
por: Mangen, Marie-Josée J., et al.
Publicado: (2015)

Cost-Effectiveness of Pneumococcal Vaccines for Adults in the United States
por: Chen, Jieling, et al.
Publicado: (2014)

Cost-utility analysis of a universal pneumococcal vaccination programme for older adults in Norway
por: Nymark, Liv Solvår, et al.
Publicado: (2022)

Personalizing pneumococcal vaccination recommendations: The Saudi Thoracic Society guidelines
por: Torres, Antoni
Publicado: (2016)

LB12. A Randomized Controlled Trial of Antibody Response to 2018–2019 Cell-based vs. Egg-based Quadrivalent Inactivated Influenza Vaccine in Children
por: Moehling, Krissy, et al.
Publicado: (2019)

Pneumococcal vaccination of older adults: Conjugate or polysaccharide?
por: Hollingsworth, Rosalind, et al.
Publicado: (2014)

647 Impact of 13-valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in the United States
por: Kim, Lindsay, et al.
Publicado: (2014)

An Assessment of the Screening Method to Evaluate Vaccine Effectiveness: The Case of 7-Valent Pneumococcal Conjugate Vaccine in the United States
por: Cohen, Adam L., et al.
Publicado: (2012)

Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccination
por: van den Biggelaar, Anita H. J., et al.
Publicado: (2017)

1097 Cost-Effectiveness of Pneumococcal Vaccines for Adults in the United States
por: Yang, H. Keri, et al.
Publicado: (2014)

Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea
por: Heo, Jung Yeon, et al.
Publicado: (2017)

Does Pneumococcal Vaccination Have an Effect on Hospital Costs?
por: Şimşek Veske, Nurdan, et al.
Publicado: (2023)

Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany
por: Kuhlmann, Alexander, et al.
Publicado: (2012)

1738. Cost-Effectiveness Analysis of Infant Pneumococcal Vaccination with the 20-Valent Pneumococcal Conjugate in the US
por: Rozenbaum, Mark, et al.
Publicado: (2023)

Awareness and Knowledge of Pneumococcal Vaccination in Cardiology Outpatient Clinics and the Impact of Physicians’ Recommendations on Vaccination Rates
por: Ekin, Tuba, et al.
Publicado: (2023)

Recommendation for use of the newly introduced pneumococcal protein conjugate vaccines in Korea
por: Choi, Eun Hwa, et al.
Publicado: (2011)

Inflammatory Mediator Expression Associated With Antibody Response Induced by Live Attenuated vs Inactivated Influenza Virus Vaccine in Children
por: Martin, Judith M, et al.
Publicado: (2018)

Pneumococcal vaccination in older persons: where are we today?
por: Van Buynder, Paul, et al.
Publicado: (2018)

Uptake of pneumococcal vaccination in older people in northern Israel
por: Eilat-Tsanani, Sophia, et al.
Publicado: (2021)

1740. Healthcare Providers’ Preferences for Pediatric Pneumococcal Vaccination Recommendations in the United States
por: Vietri, Jeffrey T, et al.
Publicado: (2023)

Pneumococcal vaccine uptake and vaccine effectiveness in older adults with invasive pneumococcal disease in Germany: A retrospective cohort study
por: Perniciaro, Stephanie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hm4t4fbnividpdh92cvip8t61q